title: Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
abstract: OBJECTIVE
  To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout.
  
  
  METHODS
  Prospective, parallel, open study of 86 consecutive male patients with primary chronic gout. Forty nine patients (26 normal excretors and 23 under excretors) were given allopurinol 300 mg/day and 37 under excretors benzbromarone 100 mg/day. After achieving steady plasma urate concentrations with such doses, treatment was then adjusted to obtain optimal plasmatic urate concentrations (under 6 mg/dl).
  
  
  RESULTS
  Patients receiving allopurinol 300 mg/day showed a mean reduction of plasmatic urate of 2.75 mg/dl (from 8.60 to 5.85 mg/dl) and 3.34 mg/dl (from 9.10 to 5.76 mg/dl) in normal excretors and under excretors respectively. Patients receiving benzbromarone 100 mg/day achieved a reduction of plasmatic urate of 5.04 mg/dl (from 8.58 to 3.54 mg/dl). Fifty three per cent of patients receiving allopurinol and 100% receiving benzbromarone achieved optimal plasma urate concentrations at such doses. The patients with poor results with allopurinol 300 mg/day achieved a proper plasma urate concentration with allopurinol 450 to 600 mg/day, the mean final dose being 372 mg/day. Renal function improved and no case of renal lithiasis was observed among benzbromarone treated patients, whose mean final dose was 76 mg/day.
  
  
  CONCLUSIONS
  Benzbromarone is very effective to control plasma urate concentrations at doses ranging from 50 to 100 mg/day. Uricosuric treatment is a suitable approach to the treatment of patients with gout who show underexcretion of urate.
authors.affiliation: Rheumatology Section, Hospital de Cruces, Pais Vasco, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Perez-Ruiz
authors.forename: A
authors.initials: A
authors.lastname: Alonso-Ruiz
authors.forename: M
authors.initials: M
authors.lastname: Calabozo
authors.forename: A
authors.initials: A
authors.lastname: Herrero-Beites
authors.forename: G
authors.initials: G
authors.lastname: García-Erauskin
authors.forename: E
authors.initials: E
authors.lastname: Ruiz-Lucea
mesh_terms: D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use*; D001553:Benzbromarone / Q000627:therapeutic use*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D006073:Gout / Q000097:blood / Q000188:drug therapy*; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014527:Uric Acid / Q000097:blood; D014528:Uricosuric Agents / Q000627:therapeutic use*
chemical_list: D006074:Gout Suppressants; D014528:Uricosuric Agents; D014527:Uric Acid; D001553:Benzbromarone; D000493:Allopurinol